PI3K/AKT/mTOR通路
蛋白激酶B
RPTOR公司
白血病
癌症研究
细胞凋亡
生物
药理学
医学
细胞生物学
信号转导
免疫学
生物化学
作者
Jessika Bertacchini,Nazanin Heidari,Laura Mediani,Silvano Capitani,Mohammad Shahjahani,Ahmad Ahmadzadeh,Najmaldin Saki
标识
DOI:10.1007/s00018-015-1867-5
摘要
Increased activity of PI3K/AKT/mTOR pathway has been observed in a huge number of malignancies. This pathway can function as a prosurvival factor in leukemia stem cells and early committed leukemic precursors and its inhibition is regarded as a therapeutic approach. Accordingly, the aim of this review is to evaluate the PI3K/Akt/mTOR inhibitors used in leukemia models. Inhibition of the PI3K/AKT/mTOR pathway has been reported to have beneficial therapeutic effects in leukemias, both in vitro in leukemia cell lines and in vivo in animal models. Overall, the use of dual PI3K/mTOR inhibitor, dual Akt/RTK inhibitor, Akt inhibitor, selective inhibitor of PI3K, mTOR inhibitor and dual PI3K/PDK1 inhibitor in CML, AML, APL, CLL, B-ALL and T-ALL has a better therapeutic effect than conventional treatments. Targeting the PI3K/Akt/mTOR pathway may have pro-apoptotic and antiproliferative effects on hematological malignancies. Furthermore, modulation of miRNA can be used as a novel therapeutic approach to regulate the PI3K/Akt/mTOR pathway. However, both aspects require further clinical studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI